A clinical trial to reduce the recurrence rate following interferon (IFN) therapy in patients with chronic hepatitis B; Effects of individualization of treatment duration according to response of serum HBV-DNA

被引：0
|
作者：
Chung, YH [1 ]
Lee, GC [1 ]
Song, BC [1 ]
Kim, HG [1 ]
Lee, YS [1 ]
Suh, DJ [1 ]
机构：
[1] UNIV ULSAN, COLL MED, ASAN MED CTR, DEPT INTERNAL MED, SEOUL, SOUTH KOREA
来源：
GASTROENTEROLOGY | 1997年 / 112卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A1245 / A1245
页数：1
相关论文
共 50 条
  • [31] INTERFERON ALFA-2B FOR CHRONIC HEPATITIS-C - EFFECTS OF DOSE INCREMENT AND DURATION OF TREATMENT ON RESPONSE RATES - RESULTS OF THE FIRST MULTICENTER AUSTRALIAN TRIAL
    LIN, R
    ROACH, E
    ZIMMERMAN, M
    STRASSER, S
    FARRELL, GC
    JOURNAL OF HEPATOLOGY, 1995, 23 (05): : 487 - 496
  • [32] IMPROVEMENT OF HISTOLOGICAL LESIONS BY 18 MONTHS THERAPY WITH ALPHA-2B INTERFERON (IFN 2B) IN PATIENTS WITH CHRONIC HEPATITIS-C - A RANDOMIZED CLINICAL-TRIAL
    POYNARD, T
    BEDOSSA, P
    CHEVALLIER, M
    MATHURIN, P
    LEMONNIER, C
    HEPATOLOGY, 1993, 18 (04) : A90 - A90
  • [33] Serum HBsAg and ddPCR HBV-DNA as predictive parameters of HBsAg loss after nucleo (s)tide analogue (NA) treatment discontinuation in non-cirrhotic patients with chronic hepatitis B
    Guerra, Anna Francesca
    Tomassoli, Giovanni
    Piermatteo, Lorenzo
    D'Anna, Stefano
    Salpini, Romina
    Svicher, Valentina
    Ventura, Paolo
    Abbati, Gian Luca
    Pietrangelo, Antonello
    JOURNAL OF HEPATOLOGY, 2022, 77 : S839 - S839
  • [34] HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B and its relation to other serum viral biomarkers
    Farag, M.
    vanCampenhout, M.
    vanBoemmel, F.
    Feld, J.
    Hansen, B.
    Janssen, H.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 7 - 7
  • [35] Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA
    Wang, Jian
    Zhu, Li
    Zhang, Shaoqiu
    Zhang, Zhiyi
    Fan, Tao
    Cao, Fei
    Xiong, Ye
    Pan, Yifan
    Li, Yuanyuan
    Jiang, Chao
    Yin, Shengxia
    Tong, Xin
    Xiong, Yali
    Xia, Juan
    Yan, Xiaomin
    Liu, Yong
    Liu, Xingxiang
    Chen, Yuxin
    Li, Jie
    Zhu, Chuanwu
    Wu, Chao
    Huang, Rui
    EMERGING MICROBES & INFECTIONS, 2024, 13 (01)
  • [36] Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients
    Lu Wei
    Yang Hai-hong
    Fan Yun-ming
    Li Takming
    Zhang Li-fan
    Mui Chongseong
    Fan Hong-wei
    Zhou Bao-tong
    Liu Zheng-yin
    Ng Hou
    Liu Xiao-qing
    CHINESE MEDICAL JOURNAL, 2013, 126 (12) : 2333 - 2336
  • [37] Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients
    Lü Wei
    YANG Hai-hong
    FAN Yun-ming
    LI Takming
    ZHANG Li-fan
    MUI Chongseong
    FAN Hong-wei
    ZHOU Bao-tong
    LIU Zheng-yin
    NG Hou
    LIU Xiao-qing
    中华医学杂志（英文版）, 2013, 126 (12) : 2333 - 2336
  • [38] Efficacy and safety of lactosaminated human serum albumia-adenine arabinoside monophosphate in chronic hepatitis B patients non-responders to interferon therapy: a randomised clinical trial
    Zarski, JP
    Barange, K
    Souvignet, C
    Bertini, M
    Marcellin, P
    Tran, A
    Deugnier, Y
    Couzigou, P
    Plages, A
    Ambroise-Thomas, P
    JOURNAL OF HEPATOLOGY, 2001, 34 (03) : 486 - 488
  • [39] Pre-treatment levels of serum IFN-λ3 more accurately predict sustained virological response by pegylated interferon/ribavirin therapy than IL28B genotyping in chronic hepatitis C patients
    Aoki, Yoshihiko
    Murata, Kazumoto
    Sugiyama, Masaya
    Kimura, Tatsuji
    Takeda, Tsutomu
    Yoshio, Sachiyo
    Korenaga, Masaaki
    Imamura, Masatoshi
    Kanto, Tatsuya
    Masaki, Naohiko
    Mizokami, Masashi
    HEPATOLOGY, 2013, 58 : 278A - 278A
  • [40] Addition of adefovir dipivoxil to lamivudine therapy results in a significant reduction in HBV DNA and serum ALT in compensated chronic hepatitis B patients with YMDD variant HBV and a reduced response to lamivudine-52 week results
    Schiff, E
    Willems, B
    Leung, N
    Lau, G
    Trepo, C
    Wright, T
    Watkins, K
    Woessner, M
    Brosgart, C
    Bourne, E
    Tait, D
    HEPATOLOGY, 2002, 36 (04) : 636A - 636A
12345